Tilray Brands, Inc.’s Post

The linked discusses the pharmaceutical industry’s efforts to influence US drug pricing reforms, particularly through significant donations to politically active groups known as “dark money” groups. According to the article, in 2022, the Department of Health and Human Services initiated Medicare price negotiations for certain drugs, prompting backlash and legal actions from pharmaceutical companies. The article highlights PhRMA’s substantial donations, including $7.5 million to a GOP-linked dark money group, American Action Network, aiming to oppose drug pricing reforms. These donations, along with contributions to other political groups, reveal a pattern of influence on both Republican and Democratic fronts regarding drug pricing policies. The lack of transparency and the impact of these actions on public health and accessibility to affordable medication for Americans is confounding. https://lnkd.in/gtERR3mE

Amgen calls Colorado’s price controls on Enbrel ‘unconstitutional’ https://lnkd.in/g9JEhbBb Amgen on Monday called on a Colorado federal court to overturn the state drug affordability board’s decision to cap the price of Amgen’s blockbuster biologic Enbrel. The California-based company said Colorado’s price controls are “unconstitutional for at least four reasons,” including that the state board does not provide “any meaningful standards” for determining why a price is considered unaffordable or how the state is setting an upper payment limit, which is expected this fall. According to Colorado’s Prescription Drug Affordability Board drug pricing and payment dashboard , Enbrel is listed third on the state’s priority list with payments of over $72 million in 2021, the last year of data provided by the state. First approved by the FDA in 1998, Enbrel isn’t likely to see biosimilar competition until 2029 . The board previously voted on Feb. 16 that Enbrel was unaffordable for… Click here to view original post Click Here to Publish/Feature Your Company or Product News with Biotech Networks

This again is an example, that this industry refuses to do their homework like any other industry. In the EU vaporisers for medicinal use are medical devices which need to be CE certified. From my perspective, thus, the use of non CE certified devices is illegal and MDs should not support such devices, and the distribution from pharmacies and pharmaceutical wholesalers is illegal. My advice for medical doctors, pharmacies, patients and other stakeholders: Be curious regrading the medical device status of the vaporiser your are using, recommend or distribute. Verband der Cannabis versorgenden Apotheken e.V. (VCA) Bundesverband pharmazeutischer Cannabinoidunternehmen e. V. European Medicinal Cannabis Association - EUMCA Bund Deutscher Cannabis-Patienten e.V. Branchenverband Cannabiswirtschaft e.V. Bundesverband der Arzneimittel-Hersteller e.V. (BAH) Bundesverband der Pharmazeutischen Industrie Bund Deutscher Cannabis-Patienten e.V. Cannabis-Startups.com Deutsche Medizinal-Cannabis Gesellschaft e. V. IACM _ International Association for Cannabinoid Medicines

I am delighted to have be appointed to the role of Chairperson of Medicines for Ireland. Generic and biosimilar medicines play a vital role in the provision of affordable, sustainable healthcare for patients in Ireland, MfI member companies supply almost 60% of all medicines used by Irish patients, a responsibility that we do not take lightly. Over the next two years it is my ambition to work on further strengthening the positive relationships that MfI has with Government, HSE, HPRA, and various other stakeholders to ensure that there is a deep understanding of the impact that generic and biosimilar medicines provide. We are operating in a time of significant change in our industry both locally and globally and it is vital therefore that the pharmaceutical ecosystem in Ireland adapts quickly to reflect the challenges that will be faced in the years ahead. #medicinesforireland #biosimilars #medicinesforeurope #genericmedicines

For the first time in its history, Medicare is set to begin negotiating directly with drugmakers to lower prescription costs. On September 1, the federal government will announce a list of the first 10 drugs that will be subject to negotiations, which is likely to include cancer and diabetes medicines used by millions. But the pharmaceutical industry will not let this happen without a fight. A flurry of lawsuits has just been filed—by four pharma giants as well as the industry’s lobbying arm, PhRMA, and the U.S. Chamber of Commerce—to preserve the industry’s ability to charge Americans more for drugs than virtually anyone else in the world. Here’s what’s happening: https://lnkd.in/gfnFVYdY

Swedish medicines regulator seeks stronger mandate to combat drug shortages The Swedish Medical Products Agency is seeking a new mandate to address drug shortages. In a recent interim report to the government, the Swedish Medical Products Agency, Läkemedelsverket, calls on the government to give the agency a clearer and stronger national role with more powers to deal with future medicine shortages. "This kind of redistribution is not possible today due to Swedish laws, but the pandemic showed the need for a national actor that could take on such work, Bengt Mattson, policy manager at LIF, the association of researched-based pharmaceutical companies in Sweden, explained to Euractiv. Mattson said he's pleased that the Swedish Medical Products Agency is now stepping forward."Swedish healthcare is fragmented, so it's great that the Medical Products Agency now wants to take on this overall and greater responsibility as a national actor," he said, adding, "We have to make sure that medicines get where they are needed. https://lnkd.in/e4NJJ3JD #PublicHealth #Europe #StayInformed #StayEmpowered

The Inflation Reduction Act (IRA) looms on the horizon, with implications for prescription drug pricing in the United States. A couple of days ago, the Centers for Medicare and Medicaid Services (CMS) released the list of drugs set for the first round of price negotiations under IRA. The Centers for Medicare and Medicaid Services (CMS) will select up to 10 Medicare Part D drugs annually for price negotiations. This number will increase to over 20 drugs by 2029. Drugs that have been on the market for ten years (small molecule) or 14 years (Biologics) are eligible to be selected by CMS. Once a drug is selected, CMS proposes a new maximum price, triggering a negotiation process with the pharmaceutical company. New prices for the first batch of drugs will kick in on the 1st of January, 2026. Needless to say, this has a direct bearing on the return on investment for these drugs. While it's tempting to get lost in the political discourse surrounding this act, let’s focus on the impact on portfolio strategy and forecasting. Certainly, the IRA will impact how we evaluate and prioritize projects and programs under development. Since the clock starts ticking when the first indication is launched, it will also impact follow-on indications using the same substance. Here are a couple of approaches on how to model this: One approach is to establish annual sales thresholds for the U.S. market. If sales after year 10+ (small molecule) exceed these thresholds, which will be incrementally lowered each year, then the model would predict lower sales in subsequent years by a pre-determined factor. This strategy offers a robust, albeit somewhat generalized, view of how the IRA will likely affect revenue. For those looking for a more nuanced understanding, another method that considers the drug's cost of goods sold (COGS), Real World Evidence, and comparative efficacy can be used. If U.S. sales exceed a particular threshold, future sales (through the price) are adjusted based on these two dimensions. This reflects the reality that the CMS initiates a negotiation process: if a drug manufacturer can show the impact on patients or comparative effect, or if the margins aren't particularly high, the price drop might be more moderate than drugs with lower impact or higher margins. It's worth noting, however, that there's still ambiguity surrounding what kinds of arguments will be admissible during these negotiations. Therefore, committing to a fixed methodology at this stage might be premature. In terms of application, the first model is excellent for quick, portfolio-wide analyses, while the second one is more aligned with granular, project-level strategic planning. Please share your own thoughts and strategies for dealing with this upcoming change in your project and portfolio modeling. #captario #modelingandsimulation #portfoliomanagement #drugdevelopment #commercialization #pharmaceuticalindustry #pharma

Exciting news for UK healthcare: 🌐 The NHS has sealed a groundbreaking deal with global drugmakers, unlocking opportunities for innovation.  The landmark deal is set to boost nation’s health, saving the NHS £14 billion and supporting research investment. Under the Voluntary Scheme for Pricing, Access, and Growth (VPAG), the annual growth cap on the UK's drug bill will rise from 2% to 4% starting 2027.  This move, supported by the Association of the British Pharmaceutical Industry, signifies a commitment to balancing access to new medicines while managing costs.  Despite some restrictions, the industry welcomes this robust agreement.  #HealthcareInnovation #Pharmaceuticals #UKNHS #MedicalAdvancements 💊 Read more on this story and other healthcare advancements 👉

For the first time, Medicare will have the authority to negotiate drug prices with pharmaceutical manufacturers. So far, there are 10 prescription drugs that will be subject to price negotiations, with the first round to formally be negotiated in 2024 and go into effect in 2026. Renee R. discusses the new changes to come for prescription drug costs here: https://bit.ly/460R3M6 #ResultsMatter

Canadian drug plans have saved more than $4 billion in the past decade. How? It's all thanks to the pCPA Generics Initiative, a joint venture between CGPA and the panCanadian Pharmaceutical Alliance (pCPA). The Initiative has provided billions of dollars in savings to participating jurisdictions, employers that sponsor drug plans for their employees, and Canadian patients. And since the prices negotiated by pCPA and CGPA are transparent and available to all payers in Canada, the additional savings to employer-sponsored drug plans and Canadian patients are estimated to be equal to that of Canadian governments. Check out CGPA's full report on International Pricing and Canada’s Generic Prescription Medicines to learn more about how the joint efforts of the pCPA and CGPA continue to help participating drug plans – and Canadian patients – save money. https://lnkd.in/ebfbZqKi.